Adrian G. Minson

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Pembrolizumab as first therapy for elderly or comorbid patients with classical Hodgkin lymphoma: Results of the phase 2 PLIMATH trial.

Pembrolizumab as first therapy for elderly or comorbid patients with classical Hodgkin lymphoma: Results of the phase 2 PLIMATH trial.

Journal: British journal of haematology

Published: July 15, 2026

Shortened axi-cel manufacturing drives rapid in vivo expansion and shifts the acute toxicity profile in R/R LBCL.

Shortened axi-cel manufacturing drives rapid in vivo expansion and shifts the acute toxicity profile in R/R LBCL.

Journal: Blood advances

Published: June 29, 2026

Dynamic risk stratification using early CAR-T expansion in R/R LBCL treated with axicabtagene ciloleucel.

Dynamic risk stratification using early CAR-T expansion in R/R LBCL treated with axicabtagene ciloleucel.

Journal: British journal of haematology

Published: June 20, 2026

Impact of peri-transplant consolidative radiotherapy in patients with relapsed or refractory classical Hodgkin lymphoma.

Impact of peri-transplant consolidative radiotherapy in patients with relapsed or refractory classical Hodgkin lymphoma.

Journal: Leukemia & lymphoma

Published: April 21, 2026

Allogeneic stem cell transplantation for mantle cell lymphoma can achieve durable remission and myeloablative conditioning is associated with inferior survival: an Australian and New Zealand Transplant & Cellular Therapies registry study.

Allogeneic stem cell transplantation for mantle cell lymphoma can achieve durable remission and myeloablative conditioning is associated with inferior survival: an Australian and New Zealand Transplant & Cellular Therapies registry study.

Journal: Internal medicine journal

Published: February 01, 2026

KR-acking the code in non-GCB DLBCL?

KR-acking the code in non-GCB DLBCL?

Journal: Leukemia & lymphoma

Published: August 03, 2025

Bispecific antibody combination therapies in diffuse large B-cell lymphoma.

Bispecific antibody combination therapies in diffuse large B-cell lymphoma.

Journal: British journal of haematology

Published: July 16, 2025

Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study.

Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 18, 2025

Routine magnetic resonance central nervous system imaging may be avoided in high-risk systemic diffuse large B-cell lymphoma with negative cerebrospinal fluid analyses.

Routine magnetic resonance central nervous system imaging may be avoided in high-risk systemic diffuse large B-cell lymphoma with negative cerebrospinal fluid analyses.

Journal: Leukemia & lymphoma

Published: January 15, 2025

Preparing Nurses for CD20-CD3 Bispecific Antibody Treatment in Patients With Non-Hodgkin Lymphoma: A Scoping Review of Adverse Events and Management Strategies From Early Phase and Pivotal Trials.

Preparing Nurses for CD20-CD3 Bispecific Antibody Treatment in Patients With Non-Hodgkin Lymphoma: A Scoping Review of Adverse Events and Management Strategies From Early Phase and Pivotal Trials.

Journal: Cancer nursing

Published: November 27, 2024

Enterocolitis associated with glofitamab-First report and clinicopathological findings in three cases.

Enterocolitis associated with glofitamab-First report and clinicopathological findings in three cases.

Journal: British journal of haematology

Published: November 02, 2024

New bispecific antibodies in diffuse large B-cell lymphoma.

New bispecific antibodies in diffuse large B-cell lymphoma.

Journal: Haematologica

Published: September 16, 2024

Showing 1-12 of 32

Last Updated: 09/26/2026